Azanidazole

Azanidazole is a nitroimidazole antiprotozoal agent that is under investigation for the treatment of Chagas disease. It is being developed by the Drugs for Neglected Diseases initiative (DNDi) and has reached Phase II clinical trials.

Mechanism of action

Azanidazole works by inhibiting the synthesis of DNA in the parasite that causes Chagas disease, Trypanosoma cruzi. This prevents the parasite from multiplying and spreading in the body.

Clinical trials

In Phase II clinical trials, azanidazole was found to be effective in treating Chagas disease. However, further studies are needed to confirm these results and to determine the optimal dosage and duration of treatment.

Side effects

The most common side effects of azanidazole include nausea, vomiting, abdominal pain, and headache. In rare cases, it can cause neuropathy or leukopenia.

Development

The development of azanidazole is part of a larger effort to find new treatments for neglected diseases. The DNDi is a non-profit organization that works to develop new treatments for diseases that are neglected by the pharmaceutical industry, including Chagas disease.

See also

• Chagas disease
• Drugs for Neglected Diseases initiative
• Nitroimidazole

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  Azanidazole